GLP-1 Medications and Birth Control: What Women Need to Know

The short answer, up front

If you take a GLP-1 medicine and rely on the pill, the medication you are on matters. The tirzepatide labels (Mounjaro and Zepbound) carry an explicit warning that oral hormonal contraceptives may become less effective, and they advise switching to a non-oral method or adding a barrier method around starting and each dose increase. Semaglutide (Ozempic, Wegovy) does not carry that warning, and a dedicated pharmacokinetic study found it did not meaningfully change the absorption of a combined pill³. This is one of the clearest examples of a women-specific difference between two drugs that are often discussed as if they were interchangeable — the same difference we weigh when we score whether a provider offers both molecules in our Luna Fit Score.

Why tirzepatide can blunt the pill — and semaglutide mostly does not

Both drug classes slow how quickly the stomach empties, which is part of how they curb appetite. That same slowing can change how fast an oral medication is absorbed. With tirzepatide the effect on gastric emptying is pronounced enough — and most pronounced when the dose is being raised — that its labeling treats reduced oral-contraceptive absorption as a real risk during initiation and every escalation step⁴. Semaglutide slows gastric emptying too, but the effect on a combined oral contraceptive was studied directly and came out clinically negligible: bioavailability of both the estrogen and progestin components was preserved³. Reviews written for OB-GYNs now flag this contrast as a practical counseling point, not a footnote⁵.

What to actually do about contraception

The reassuring part is that the concern is specific to *oral* absorption. Non-oral methods bypass the stomach entirely, so a hormonal IUD, the implant, the injection, the patch or the vaginal ring are not affected by delayed gastric emptying — and neither are copper IUDs or barrier methods. Practical options if you are starting tirzepatide and currently use the pill: switch to one of those non-oral methods, or keep the pill and add condoms for the first four weeks after starting and for four weeks after each dose increase, which is the window the labeling flags. On semaglutide the pill can generally be continued, but the safest move is always to raise it with your prescriber before your first injection rather than after⁶. A provider who actually reviews your history — the kind our top-ranked CoreAge Rx is scored on — should bring this up without being asked.

“Ozempic babies”: the fertility catch nobody mentions at the pharmacy

Alongside the absorption question is a second, separate reason women on these drugs report surprise pregnancies. Losing a meaningful amount of weight and improving insulin sensitivity can restore more regular ovulation, especially in women with PCOS, where anovulation is common⁷ — which is also why GLP-1 treatment comes up so often for women actively pursuing pregnancy through fertility treatment, a distinct set of timing questions our guide to GLP-1 before IVF covers. Weight-loss trials show why the effect can be substantial: once-weekly semaglutide produced roughly 15% mean body-weight reduction in STEP 1, and tirzepatide reached around 20% in SURMOUNT-1¹². Broader reviews of medical weight loss report improved fertility markers as weight comes down⁸, and incretin therapies have been studied specifically for restoring ovulatory cycles in PCOS⁹. So a woman who assumed she could not easily conceive may become more fertile at the same time her pill is (if she is on tirzepatide) potentially less reliable — two independent effects pushing the same direction. Narrative reviews of GLP-1 use in reproductive-age women now treat this fertility-restoration signal as a counseling priority, not a curiosity¹⁰.

Why pregnancy timing is the non-negotiable part

GLP-1 medicines are not recommended in pregnancy, and this is where the two effects above stop being academic. Because a surprise pregnancy is more likely than many women expect, and because these drugs should be stopped before conception, contraception during treatment is genuinely part of using them responsibly. Semaglutide has a long half-life of about a week, so its labeling advises discontinuing it at least two months before a planned pregnancy; tirzepatide should be stopped when pregnancy is recognized. Human pregnancy-exposure data remain limited to small case series and registries rather than controlled trials, which is exactly why the guidance leans conservative¹¹. None of this means the drugs are unsafe to use — it means the plan has to include reliable contraception and a clear stop-before-trying strategy, ideally set with a clinician who understands your reproductive goals⁵. If you are tracking cycle symptoms alongside all of this, our guide on GLP-1s, your cycle and hormones walks through what is worth monitoring, and our which markers a program should be watching over time covers what to check over the first months.

Bring these to your provider

Ask which molecule you are being prescribed and whether it carries the oral-contraceptive caution; ask whether a non-oral method makes sense for you; and ask how the program handles pregnancy planning and washout if you decide to try to conceive. The same reproductive-timeline questions come back around after a pregnancy, too — if you're breastfeeding and weighing whether to start or resume a GLP-1, the FDA label treats the tablet and the injection differently, which we explain in what the evidence shows on GLP-1 and breastfeeding. These are the same access-and-oversight questions that separate a real women's-metabolic program from a mail-order vial, and they are worth confirming before your first dose — not after. This guide is educational only and not medical advice.